Feb 28, 2013, 09.36 AM | Source: PTI
Drug firm Jubilant Life Sciences today said US health regulator has issued a warning letter for violation of manufacturing norms at its facility in Canada.
"Jubilant HollisterStier General Partnership (JHS) located at Kirkland, Quebec, Canada has been issued a warning letter (WL) by US Food and Drug Administration (FDA) identifying significant violations of current good
manufacturing practices (cGMP) regulations," Jubilant Life Sciences said in a filing to the BSE.
As required by FDA, JHS will respond to this letter by March 15, 2013, it added.
"The response will provide details as to what corrective action has already been completed, as well as, additional detail as to how the facility will prevent the re occurrence of the items found to be objectionable to the FDA," Jubilant Life Sciences said.
USFDA had specified in its letter that until all corrections have been completed, it may withhold approval of new applications or supplements listing JHS as the drug product manufacturer.
"We expect that the on-going manufacturing, distribution and sale of products will not be affected by this warning letter. JHS is committed to implementing the necessary corrective actions required to address the FDA concerns, and
will work closely with the FDA to bring resolution to this matter," it added.
Shares of Jubilant Life Sciences today closed at Rs 176.45 per scrip on BSE, down sharp 4.90 percent from its previous close.
Jubilant Life stock price
On May 02, 2016, Jubilant Life Sciences closed at Rs 391.90, down Rs 8.15, or 2.04 percent. The 52-week high of the share was Rs 455.00 and the 52-week low was Rs 147.00.
The latest book value of the company is Rs 122.11 per share. At current value, the price-to-book value of the company was 3.21.
The product is being recalled on account of "label
Ajay Bodke of Prabhudas Lilladher has a positive v
This deal is a testimony to the company's investme
Jubilant Innovation USA Inc, subsidiary of Jubilan
Ashwani Gujral of ashwanigujral.com is of the view
Ashwani Gujral of ashwanigujral.com recommends buy
Housing Development Finance Corporation has in-pri
The Indian lender owned 61.63 percent of the joint